Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics.

Authors: F Wincott; A DiRenzo; C Shaffer; S Grimm; D Tracz; C Workman; D Sweedler; C Gonzalez; S Scaringe; N Usman
Journal: Nucleic Acids Res Date: 1995-07-25 Impact factor: 16.971

7. Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance.

Authors: L Beigelman; J A McSwiggen; K G Draper; C Gonzalez; K Jensen; A M Karpeisky; A S Modak; J Matulic-Adamic; A B DiRenzo; P Haeberli
Journal: J Biol Chem Date: 1995-10-27 Impact factor: 5.157

8. Poliovirus chimeras replicating under the translational control of genetic elements of hepatitis C virus reveal unusual properties of the internal ribosomal entry site of hepatitis C virus.

Authors: H H Lu; E Wimmer
Journal: Proc Natl Acad Sci U S A Date: 1996-02-20 Impact factor: 11.205

9. In vitro splicing of the ribosomal RNA precursor of Tetrahymena: involvement of a guanosine nucleotide in the excision of the intervening sequence.

Authors: T R Cech; A J Zaug; P J Grabowski
Journal: Cell Date: 1981-12 Impact factor: 41.582

10. Sequence analysis of the 5' noncoding region of hepatitis C virus.

Authors: J Bukh; R H Purcell; R H Miller
Journal: Proc Natl Acad Sci U S A Date: 1992-06-01 Impact factor: 11.205

20 in total

1. Developing aptamers into therapeutics.

Authors: R R White; B A Sullenger; C P Rusconi
Journal: J Clin Invest Date: 2000-10 Impact factor: 14.808

Review 2. Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function.

Authors: L M Khachigian
Journal: J Clin Invest Date: 2000-11 Impact factor: 14.808

Review 3. Angiogenesis and melanoma.

Authors: J P Dutcher
Journal: Curr Oncol Rep Date: 2001-07 Impact factor: 5.075

Review 4. Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies.

Authors: Ravinay Bhindi; Roger G Fahmy; Harry C Lowe; Colin N Chesterman; Crispin R Dass; Murray J Cairns; Edward G Saravolac; Lun-Quan Sun; Levon M Khachigian
Journal: Am J Pathol Date: 2007-08-23 Impact factor: 4.307

Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics.

1. Viral hepatitis.

Review 2. The regulation of blood vessel growth by vascular endothelial growth factor.

Review 3. Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides.

Review 4. Hepatitis C: the clinical spectrum of disease.

Review 5. Vascular endothelial growth factor, a potent and selective angiogenic agent.

6. Synthesis, deprotection, analysis and purification of RNA and ribozymes.

7. Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance.

8. Poliovirus chimeras replicating under the translational control of genetic elements of hepatitis C virus reveal unusual properties of the internal ribosomal entry site of hepatitis C virus.

9. In vitro splicing of the ribosomal RNA precursor of Tetrahymena: involvement of a guanosine nucleotide in the excision of the intervening sequence.

10. Sequence analysis of the 5' noncoding region of hepatitis C virus.

1. Developing aptamers into therapeutics.

Review 2. Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function.

Review 3. Angiogenesis and melanoma.

Review 4. Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies.

Review 5. Therapeutic regulation of gene expression in the inner ear using RNA interference.

Review 6. Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.

Review 7. Inhibition of vascular endothelial growth factor in the treatment of solid tumors.

Review 8. Targeted therapy for malignant melanoma.

Review 9. In vivo imaging with oligonucleotides for diagnosis and drug development.

10. Internal 32P-labeling of L-deoxyoligonucleotides.